Hypertrophic cardiomyopathy in childhood and adolescence - Strategies to prevent sudden death

Fundamental and Clinical Pharmacology

Volumn 24, Issue 5, 2010, Pages 637-652

  Östman Smith, Ingegerd ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

beta blockers; disopyramide; hypertrophic cardiomyopathy; propranolol; sudden death mortality

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; METOPROLOL; PROPRANOLOL; SPIRONOLACTONE; VERAPAMIL;

ADOLESCENCE; AGE DISTRIBUTION; ASTHMA; ATHLETE; BLADDER EMPTYING; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHILDHOOD; CHILDHOOD MORTALITY; COHORT ANALYSIS; CONSTIPATION; DEFIBRILLATOR; DRUG DOSE TITRATION; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; EYE TOXICITY; FAMILIAL DISEASE; FAMILY ASSESSMENT; FAMILY HISTORY; GENDER; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART MURMUR; HEART MUSCLE FIBROSIS; HEART OUTFLOW TRACT OBSTRUCTION; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOGLYCEMIA; HYPOKALEMIA; IMPOTENCE; LEOPARD SYNDROME; LIFESTYLE MODIFICATION; LIVER TOXICITY; LONG TERM CARE; LUNG EDEMA; LUNG TOXICITY; MORBIDITY; MYOCARDIAL BRIDGING; NOONAN SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PUBERTY; QRS COMPLEX; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING; SECONDARY PREVENTION; SHOCK; SIDE EFFECT; SKIN TOXICITY; SLEEP DISORDER; STRATIFIED SAMPLE; SUDDEN DEATH; SWEATING; SYNCOPE; ULTRASOUND; UNSPECIFIED SIDE EFFECT; VIVID DREAM; XEROSTOMIA;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; HUMANS; RISK FACTORS; YOUNG ADULT;

EID: 77956953740     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00869.x     Document Type: Review

References (83)

1. Sugishita Y., Matsuda M., Iida K., Koshinaga J., Ueno M. Sudden cardiac death at exertion. Jpn. Circ. J. (1983) 47 562 572.
2. Maron B., Roberts W., McAllister H., Rosing D., Epstein S. Sudden death in young athletes. Circulation (1980) 62 218 229.
3. Östman-Smith I., Wettrell G., Keeton B. et al. Age-and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur. Heart J. (2008) 29 1160 1167.
4. Hada Y., Sakamoto T., Amano K. et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am. J. Cardiol. (1987) 59 183 184.
5. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation (1995) 92 785 789.
6. Maron B.J., Spirito P., Roman M.J. et al. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am. J. Cardiol. (2004) 93 1510 1514.
7. Östman-Smith I., Wettrell G., Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J. Am. Coll. Cardiol. (1999) 34 1813 1822.
8. Arola A., Jokinen E., Ruuskanen O. et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents: a nationwide study in Finland. Am. J. Epidemiol. (1997) 146 385 393.
9. Maron B.J., Seidman J.G., Seidman C.E. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. (2004) 44 2125 2132.
10. Wren C., O'Sullivan J.J., Wright C. Sudden death in children and adolescents. Heart (2000) 83 410 413.
11. Nugent A., Daubeney P., Chondros P. et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation (2005) 112 1332 1338.
12. Colan S.D., Lipshultz S.E., Lowe A.M. et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry. Circulation (2007) 115 773 781.
13. Pelliccia A., Di Paolo F.M., Corrado D. et al. Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. Eur. Heart J. (2006) 27 2196 2200.
14. Corrado D., Basso C., Pavei A., Michieli P., Schiavon M., Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA (2006) 296 1593 1601. (Pubitemid 44515020)
15. Elston J., Stein K. Public health implications of establishing a national programme to screen young athletes in the UK. Br. J. Sports Med. (2009) E-pub ahead of print, doi:.
16. Östman-Smith I., Wisten A., Nylander E. et al. Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy. Eur. Heart J. (2010) 31 439 449. Epub ahead of print, Nov 5, 2009, doi:.
17. Maron B.J., McKenna W., Danielson G.K. et al. American College of Cardiology/European Society of Cardiology clinical consensus document on hypertrophic cardiomyopathy. Eur.Heart J. (2003) 24 1965 1991.
18. Semsarian C., French J., Trent R.J., Richmond D.R., Jeremy R.W. The natural history of left ventricular wall thickening in hypertrophic cardiomyopathy. Aust. NZ J. Med. (1997) 27 51 58.
19. McKenna W.J., Stewart J.T., Nihoyannopoulos P., McGinty F., Davies M.J. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br. Heart. J. (1990) 63 287 290.
20. Varnava A., Baboonian C., Davison F., de Cruz L., Elliott P.M., Davies M.J. et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart (1999) 82 621 624.
21. Konno T., Shimizu M., Ino H. et al. Differences in diagnostic value of four electrocardiographic voltage criteria for hypertrophic cardiomyopathy in a genotyped population. Am. J. Cardiol. (2005) 96 1308 1312.
22. Östman-Smith I., Bratt E.-L., de-Wahl Granelli A. Frequency of diagnostic ECG-abnormalities in children of parents with familial hypertrophic cardiomyopathy. Cardiol. Young (2007) 17 (Suppl 1) 60.
23. Charron P., Dubourg O., Desnos M. et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation (1997) 96 214 219.
24. Konno T., Shimizu K., Ino H. et al. Phenotypic differences between electrocardiographic and echocardiographic determination of hypertrophic cardiomyopathy in genetically affected subjects. J. Intern. Med. (2005) 258 216 224.
25. Elliott P.M., Poloniecki J., Dickie S. et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J. Am. Coll. Cardiol. (2000) 36 2212 2218.
26. Cecchi F., Olivotto I., Montereggi A., Squillatini G., Dolara A., Maron B.J. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart (1998) 79 331 336.
27. Olivotto I., Maron B.J., Montereggi A., Mazzuoli F., Dolara A., Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. (1999) 33 2044 2051.
28. Elliott P.M., Gimeno Blanes J.R., Mahon N.G., Poloniecki J.D., McKenna W.J. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 357 420 424.
29. Hess O.M. Risk stratification in hypertrophic cardiomyopathy. Fact or fiction? J. Am. Coll. Cardiol. (2003) 42 880 881.
30. Yetman A.T., Hamilton R.M., Benson L.N., McCrindle B.W. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. (1998) 32 943 950.
31. McKenna W.J., Deanfield J.E. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch. Dis. Child. (1984) 59 971 975.
32. Romeo F., Cianfrocca C., Pelliccia F., Colloridi V., Cristofani R., Reale A. Long-term prognosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less than 14 years at diagnosis. Clin. Cardiol. (1990) 13 101 107.
33. McKenna W., Deanfield J., Faruqui A., England D., Oakley C., Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am. J. Cardiol. (1981) 47 532 538.
34. Decker J.A., Rossano J.W., O'Brian Smith E. et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J. Am. Coll. Cardiol. (2009) 54 250 254.
35. Östman-Smith I., Wettrell G., Keeton B., Riesenfeld T., Holmgren D., Ergander U. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol. Young (2005) 15 632 642.
36. McLeod C.J., Ackerman M.J., Nishimura R.A., Tajik A.J., Gersh B.J., Ommen S.R. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J. Am. Coll. Cardiol. (2009) 54 229 233.
37. Pelliccia A., Corrado D., Bjornstad H.H. et al. Recommendations for participation in competitive sports and leisure-time activities in individuals with cardiomyopathies, myocarditis and pericarditis. Eur. J. Cardiovasc. Prev. Rehabil. (2006) 13 876 885.
38. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res. Cardiol. (2000) 95 (Suppl 1) 141 145.
39. Nadamanee K., Taylor R., Bailey W.E., Rieders D.E., Kosar E.M. Treating electrical storm: sympathetic blockade versus advanced life support-guided therapy. Circulation (2000) 102 742 747.
40. Chorro F.J., Trapero I., Such-miquel L. et al. Pharmacological modifications of stretch-induced effects on ventricular fibrillation in perfused rabbit hearts. Am. J. Physiol. Heart. Circ. Physiol. (2009) 297 H1860 H1869 [Epub ahead of print, Sept 11].
41. Thaman R., Elliott P.M., Shah J.S. et al. Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. (2005) 46 883 892.
42. Melacini P., Maron B.J., Bobbo F. et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart (2007) 93 708 710.
43. Frank M.J., Abdulla A.M., Canedo M.I., Saylors R.E. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am. J. Cardiol. (1978) 42 993 1001.
44. Frank M.J., Stefadouros M.A., Watkins L.O., Prisant L.M., Abdulla A.M. Rhythm disturbances in hypertrophic cardiomyopathies: relationship to symptoms and the effect of 'complete'β blockade. Eur. Heart J. (1983) 4 (Suppl F) 235 243.
45. Östman-Smith I., Wettrell G., Holmgren D., Keeton B., Ergander U. The effect of beta-blocker dose on disease progression in children with hypertrophic cardiomyopathy. Scand. Cardiovasc. J. (2005) 39 (Suppl 53) 36 37.
46. Zhou S.H. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. (2009) 48 689 723.
47. Albers S., Meibohm B., Mir T.S., Läer S. Population pharmacokinetics and dose simulation of carvedilol in pediatric patients with congestive heart failure. Br. J. Clin. Pharmacol. (2008) 65 511 522.
48. Huffman J., Stern T. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin. Neurosci. (2007) 9 29 45.
49. Bratt E.-L., de-Wahl Granelli A., Östman-Smith I. Effect of high-dose beta-blocker on exercise capacity in patients with hypertrophic cardiomyopathy. Cardiol. Young (2007) 17 (Suppl 1) 40 41.
50. Bratt E.-L., de-Wahl Granelli A., Östman-Smith I. Selective or non-selective beta-blockade - evaluation of exercise capacity in children and adolescents with hypertrophic cardiomyopathy. 5th World Congress of Paediatric Cardiology and Cardiac Surgery. http://www.pcccs2009.com.
51. Bourmayan C., Razavi A., Fournier C. et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. Am. Heart J. (1985) 109 1311 1316.
52. Kaltenbach M., Hopf R., Kober G., Bussmann W.D., Keller M., Petersen Y. Treatment of hypertrophic cardiomyopathy with verapamil. Br. Heart. J. (1979) 42 35 42.
53. Rosing D.R., Kent K.M., Maron B.J., Condit J., Epstein S.E. Verapamil therapy: a new approach to pharmacologic treatment of hypertrophic cardiomyopathy. Chest (1980) 78 239 247.
54. Spicer R.L., Rocchini A.P., Crowley D.C., Rosenthal A. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. Am. J. Cardiol. (1984) 53 1614 1619.
55. Epstein S.E., Rosing D.R. Verapamil: its potential for causing serious complication in patients with hypertrophic cardiomyopathy. Circulation (1981) 64 437 441.
56. Pelliccia F., Cianfrocca C., Romeo F., Reale A. Hypertrophic cardiomyopathy - long-term effects of propranolol versus verapamil in preventing sudden death in low-risk patients. Cardiovasc. Drugs Ther. (1990) 4 1515 1518.
57. Östman-Smith I., Keeton B., Wettrell G. Effect of medical therapy in childhood hypertrophic cardiomyopathy with risk factors for heart-failure related death. Cardiol. Young (2008) 18 (Suppl 1) 10.
58. Pollick C. Disopyramide in hypertrophic cardiomyopathy. II. Non-invasive assessment after oral administration. Am. J. Cardiol. (1988) 62 1252 1255.
59. Matsubara H., Nakatani S., Nagata S. et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. (1995) 26 768 775.
60. Cokkinos D.V., Salpeas D., Ioannou N.E. Combination of disopyramide and propranolol in hypertrophic cardiomyopathy. Can. J. Cardiol. (1989) 5 33 36.
61. Duncan W.J., Tyrrell M.J., Bharadwaj B.B. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can. J. Cardiol. (1991) 7 81 86.
62. Teraguchi M., Ikemoto Y., Kobayashi Y. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy. Circ. J. (2002) 66 709 711.
63. Campbell R.W., Nimkhedkar K. Risk-benefit profiles of antiarrhythmic therapy. Am. J. Cardiol. (1989) 64 50j 52j.
64. Griffith M.J., Linker N.J., Garrett C.J., Ward D.E., Camm A.J. Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. Lancet (1990) 336 670 673.
65. Sherrid M.V., Barac I., McKenna W.J. et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. (2005) 45 1251 1258.
66. Siddoway L.A., Woosley R.L. Clinical pharmacokinetics of disopyramide. Clin. Pharmacokinet. (1986) 11 214 222.
67. McKenna W.J., Oakley C.M., Krikler D.M., Goodwin J.F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br. Heart. J. (1985) 53 412 416.
68. Vrobel T.R., Miller P.E., Mostow N.D., Rakita L. A general overview of amiofdarone toxicity: its prevention, detection and management. Prog. Cardiovasc. Dis. (1989) 31 393 426.
69. Kannan R., Yabek S.M., Garson A. Jr., Miller S., McVey P., Singh B.N. Amiodarone efficacy in a young population: relationship to serum amiodarone and desethylamiodarone levels. Am. Heart J. (1987) 114 283 287.
70. Paulus W.J., Nellens P., Heyndrickx G.R., Andries E. Effects of long-term treatment with amiodarone on exercise hemodynamics and left ventricular relaxation in patients with hypertrophic cardiomyopathy. Circulation (1986) 74 544.
71. Fananapazir L., Leon M.B., Bonow R.O., Tracy C.M., Cannon R.O., Epstein S.E. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am. J. Cardiol. (1991) 67 169 174.
72. Elliott P.M., Sharma S., Varnava A., Poloniecki J., Rowland E., McKenna W.J. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. (1999) 33 1596 1601.
73. Le Heuzey J.Y., De Ferrari G.M., Radzik D., Santini M., Zhu J., Davy J.M. A Short-Term, Random,ized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol. (2010) 21 597 605 [Epub ahead of print].
74. Damy T., Pousset F., Caplain H., Hulot J.S., Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam. Clin. Pharmacol. (2004) 18 113 123.
75. Lenz T.L., Hilleman D.E. Dofetilide: a new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/flutter. Drugs Today (2000) 36 759 771.
76. Hohnloser S.H., Verrier R.L., Lown B., Raeder E.A. Effect of hypokalaemia on susceptibility to ventricular fibrillation in the normal and ischemic canine heart. Am. Heart J. (1986) 112 32 35.
77. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341 709 717.
78. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation (2000) 102 2700 2706.
79. Tsybouleva N., Zhang L., Chen S. et al. Aldosterone, through novel signalling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 109 1284 1291.
80. Maron B.J., Spirito P., Shen W.-K. et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 298 405 412. (Pubitemid 47124061)
81. Thaman R., Gimeno J.R., Reith S. et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J. Am. Coll. Cardiol. (2004) 44 398 405.
82. Heersche J.H., Blom N.A., Van de Heuvel F. et al. Implantable Cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands. Pacing Clin. Electrophysiol. (2009) 33 179 185.
83. Bollmann A., Husser D., Cannom D.S. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. Am. J. Cardiovasc. Drugs (2005) 5 371 378.